Výsledky vyhledávání - "K. Pateromichelaki"

POS0368 EARLY (3 MONTHS) IMPROVEMENT IN PHYSICIAN GLOBAL ASSESSMENT OF DISEASE ACTIVITY PREDICTS LONG-TERM RETENTION OF BELIMUMAB TREATMENT IN SLE: A MULTICENTRE OBSERVATIONAL STUDY OF 184 PATIENTS

Autor: M. Nikoloudaki, D. Nikolopoulos, S. Koutsoviti, I. Flouri, N. Kapsala, A. Repa, P. Katsimpri, E. Theotikos, S. Pitsigavdaki, K. Pateromichelaki, A. Eskitzis, A. Elezoglou, P. Sidiropoulos, A. Fanouriakis, D. Boumpas, G. Bertsias

Publikováno v: Annals of the Rheumatic Diseases. 81:437-438

BackgroundBelimumab has been introduced in the management of SLE for more than 10 years, however long-term efficacy and safety data are still limited and mostly derive from the extended phase of randomized clinical trials.ObjectivesTo evaluate the lo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4d7c27bb42e66965611cea73fec8f20c
https://doi.org/10.1136/annrheumdis-2022-eular.4735

Zobrazit plný text záznamu

AB0375 IN PATIENTS STARTING ETANERCEPT, MALE SEX, ABSENCE OF COMORBIDITIES AND NO csDMARDs CO-ADMINISTRATION ARE INDEPENDENT PREDICTORS OF LONG-TERM (MORE THAN 3 YEARS) PERSISTENCE TO THERAPY, IRRESPECTIVELY OF THE CLINICAL DIAGNOSIS

Autor: I. Flouri, A. Repa, N. Avgustidis, A. Eskitzis, A. Molla Ismail Sali, S. Pitsigavdaki, K. Pateromichelaki, A. Bertsias, E. Kalogiannaki, M. Terizaki, G. Bertsias, P. Sidiropoulos

Publikováno v: Annals of the Rheumatic Diseases. 81:1314.2-1315

BackgroundComparative data among rheumatoid arthritis (RA), spondylarthritis (SpA) and psoriatic arthritis (PsA) patients regarding long-term survival of etanercept (ETN) in clinical practice are limited.ObjectivesThe first aim of this study was to a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b0fad950e615f17c4173f28c0488dcfd
https://doi.org/10.1136/annrheumdis-2022-eular.4826

Zobrazit plný text záznamu

POS0941 IN SPONDYLOARTHRITIS PATIENTS THE PRESENCE OF COMORBIDITIES IS AN INDEPENDENT PREDICTOR OF INSUFFICIENT RESPONSE TO THERAPY WITH BIOLOGIC AGENTS AND TREATMENT DISCONTINUATION

Autor: A. Molla Ismail Sali, Argyro Repa, A. Eskitzis, S. Pitsigavdaki, Nikolaos Kougkas, K. Pateromichelaki, N. Avgustidis, Prodromos Sidiropoulos, E. Kalogiannaki, Irini Flouri, G. Bertsias

Publikováno v: Annals of the Rheumatic Diseases. 80:733.2-734

Background:Long-term observational studies of patients under biologic disease-modifying anti-rheumatic drug (bDMARD) therapies in routine clinical practice can provide us with important data regarding patients with comorbidities, who are usually excl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d29079d93be25fc7f059cb16814b12e3
https://doi.org/10.1136/annrheumdis-2021-eular.4222

Zobrazit plný text záznamu

OP0299 IN RHEUMATOID ARTHRITIS PATIENTS HIGHER NUMBER OF COMORBIDITIES PREDICTS 6-MONTH INSUFFICIENT RESPONSE TO FIRST BIOLOGIC THERAPY AND EVENTUAL CATEGORIZATION OF THE DISEASE AS DIFFICULT-TO-TREAT

Autor: S. Pitsigavdaki, K. Pateromichelaki, A. Molla Ismail Sali, A. Eskitzis, E. Kalogiannaki, Argyro Repa, N. Avgustidis, Nikolaos Kougkas, Prodromos Sidiropoulos, M. Terizaki, Irini Flouri, G. Bertsias

Publikováno v: Annals of the Rheumatic Diseases. 80:184.2-184

Background:Difficult-to-treat rheumatoid arthritis (D2T RA) was recently defined by a EULAR study group (1) and, as a disease category it is largely complicated and under-researched. Patient comorbidities may play a significant role in the response t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9c785ac95f24109adcc168c281672a96
https://doi.org/10.1136/annrheumdis-2021-eular.4110

Zobrazit plný text záznamu

POS0580 COMORBIDITY BURDEN IS HIGH IN RHEUMATOID ARTHRITIS AND SPONDYLOARTHRITIS PATIENTS STARTING BIOLOGICS AND PREDICTS THE INCIDENCE OF SERIOUS ADVERSE EVENTS DURING THERAPY

Autor: N. Avgustidis, A. Molla Ismail Sali, K. Pateromichelaki, A. Eskitzis, Prodromos Sidiropoulos, Nikolaos Kougkas, S. Pitsigavdaki, M. Terizaki, Irini Flouri, G. Bertsias, Argyro Repa, E. Kalogiannaki

Publikováno v: Annals of the Rheumatic Diseases. 80:523.2-523

Background:There is limited information on the burden of comorbidities in patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA) in real-world clinical practice and its impact on the incidence of serious adverse events (SAE) during biolo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4600d0d13f12592356fcf6a303e92bac
https://doi.org/10.1136/annrheumdis-2021-eular.3956

Zobrazit plný text záznamu

AB1041 BIOLOGICS IN ADULT’S ONSET STILL’S DISEASE: TREATMENT STRATEGIES AND SAFETY IN SINGLE CENTER COHORT WITH LONG-TERM FOLLOW-UP

Autor: Argyro Repa, S. Pitsigavdaki, K. Pateromichelaki, A. Molla Ismail Sali, A. Eskitzis, G. Bertsias, N. Avgustidis, Nikolaos Kougkas

Publikováno v: Annals of the Rheumatic Diseases. 79:1811.1-1812

Background:Adult-onset Still’s disease (AOSD) is a rare systemic inflammatory disorder. In recent years biological disease modifying antirheumatic drugs (bDMARDs) are becoming increasingly important for its treatment.Objectives:To evaluate disease

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::288f3b53c745bfef776c2d96fb9364dd
https://doi.org/10.1136/annrheumdis-2020-eular.4120

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání